Original ResearchFull Report: Clinical—LiverEffectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
Section snippets
Patients
The ANRS CO20-CUPIC cohort is a national multicenter prospective cohort study conducted in 56 French centers (ClinicalTrials.gov number: NCT01514890). From February 2011 to April 2012, patients with compensated cirrhosis (Child–Pugh class A) chronically infected with HCV genotype 1 who failed a prior course of IFN with or without RBV and started triple combination therapy in the French Early Access Program in the participating centers were included. Initially, only relapsers (or patients with a
Baseline Demographics and Disease Characteristics
A total of 660 patients older than 18 years of age were enrolled in 56 centers; 511 patients reached week 60 of follow-up evaluation and thus were included in this analysis, including 299 treated with TVR and 212 treated with BOC. The baseline demographics and disease characteristics are shown in Table 1. Of the 511 patients, 346 (67.7%) were men, and their mean age was 57.0 ± 9.7 years. The prior treatment response was a relapse or a virologic breakthrough in 226 cases (44.3%, including 17
Discussion
The CUPIC cohort is a large cohort of treatment-experienced cirrhotic patients infected with HCV genotype 1 treated with BOC or TVR in combination with peg-IFN and RBV in the real-life setting. Because the choice of TVR or BOC was made by the treating physicians and the patients were not randomized, no comparison can be made between the 2 PIs. However, our results provide, for each drug regimen, an accurate reflection of what can be expected in terms of antiviral efficacy and safety in this
Acknowledgments
The authors thank David Marsh for writing assistance.
References (33)
- et al.
Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis
Clin Gastroenterol Hepatol
(2006) - et al.
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study
J Hepatol
(2009) - et al.
Guidelines for the diagnosis of uncomplicated cirrhosis
Gastroenterol Clin Biol
(2007) - et al.
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals
J Hepatol
(2012) - et al.
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890
J Hepatol
(2013) - et al.
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis
J Hepatol
(2013) - et al.
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
J Hepatol
(2014) - et al.
The natural history of compensated HCV-related cirrhosis: a prospective long-term study
J Hepatol
(2013) - et al.
Safety and efficacy of boceprevir/peginterferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analysis of five phase 3 clinical trials
J Hepatol
(2013) - et al.
Boceprevir for untreated chronic HCV genotype 1 infection
N Engl J Med
(2011)
Boceprevir for previously treated chronic HCV genotype 1 infection
N Engl J Med
Telaprevir for previously untreated chronic hepatitis C virus infection
N Engl J Med
Telaprevir for retreatment of HCV infection
N Engl J Med
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study
Am J Gastroenterol
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C
Hepatology
The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients
Hepatology
Cited by (229)
Drug-Induced Liver Injury in the Setting of Chronic Liver Disease
2020, Clinics in Liver DiseaseImmunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming
2018, Infection, Genetics and EvolutionChallenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018, Journal of HepatologyTherapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus
2024, Current Medicinal Chemistry
Authors names in bold designate shared co-first author.
Conflicts of interest These authors disclose the following: Christophe Hézode has been a clinical investigator, speaker, and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Hélène Fontaine has been a clinical investigator and/or speaker for Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck Sharp and Dohme, Gilead Sciences, and Roche; Fabien Zoulim has been a speaker and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Dominique Larrey has been a clinical investigator, speaker, and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Valérie Canva has been a clinical investigator and/or speaker for Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Victor de Ledinghen has been a clinical investigator, speaker, and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Thierry Poynard has been a clinical investigator, speaker, and/or consultant for Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, and Merck Sharp and Dohme; Didier Samuel has been a consultant for Astellas, Biotest, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Laboratoire Français du Fractionnement et des Biotechnologies, Merck Sharp and Dohme, Novartis, and Roche; Marc Bourlière has been a clinical investigator, speaker, and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Glaxo Smith Kline, Janssen Pharmaceuticals, Merck Sharp and Dohme, Roche, and Vertex; Laurent Alric has been a clinical investigator, speaker, and/or consultant for Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Jean-Pierre Zarski has been a speaker and/or consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, Roche, and Siemens; Patrick Marcellin has been a clinical investigator, speaker, and/or consultant for Abbvie, Alios BioPharm, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, Novartis, Pfizer, Roche, and Vertex Pharmaceuticals; Véronique Loustaud-Ratti has been a clinical investigator, speaker, and/or consultant for Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche, and has received grant/research support from Bristol-Myers Squibb and Roche; Olivier Chazouilleres has been a clinical investigator, speaker, and/or consultant for Aptalis, Echosens, Gilead Sciences, Mayoly-Spindler, and Roche; Armand Abergel has been a clinical investigator, speaker, and/or consultant for Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Dominique Guyader has been a clinical investigator, speaker, and/or consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Albert Tran has been a clinical investigator for Janssen Pharmaceuticals and Merck Sharp and Dohme; Vincent Di Martino has been a clinical investigator, speaker, and/or consultant for Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Roche; Xavier Causse has been a consultant for Janssen Pharmaceuticals and Merck Sharp and Dohme; Thong Dao has been a consultant for Gilead Sciences and Merck Sharp and Dohme; Patrice Cacoub has received consulting and lecture fees from Bristol-Myers Squibb, Gilead, Roche, Merck Sharp, Servier, and Vifor; Jérome Gournay has been a speaker and/or consultant for Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Patrick Hillon has been a clinical investigator, speaker, and/or consultant for Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, and Roche; Pierre Attali has been a clinical investigator for Boehringer Ingelheim, Bristol-Myers Squibb, Cytheris, Gilead Sciences, and Novartis; Thierry Fontanges has been a speaker and/or consultant for Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, and Merck Sharp and Dohme; Isabelle Rosa has been a speaker and/or consultant for Janssen Pharmaceuticals and Merck Sharp and Dohme; Jean-Michel Pawlotsky has received research grants from Gilead Sciences, and has served as an advisor for Abbott, Abbvie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Janssen Therapeutics, Merck, Novartis, and Roche; Stanislas Pol has received consulting and lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Tibotec, Vertex, Gilead, Roche, Schering-Plough/Merck, Novartis, Abbott/Abbvie, Sanofi, and Glaxo Smith Kline, and grants from Bristol-Myers Squibb, Gilead, Roche, and Merck/Schering Plough; and Jean-Pierre Bronowicki has been a clinical investigator, speaker, and/or consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp and Dohme, Novartis, and Roche. The remaining authors disclose no conflicts.
Funding Sponsored and funded by the National Agency for Research on AIDS and Viral Hepatitis and in part by the Association Française pour l'Etude du Foie.
Additional Compassionate Use of Protease Inhibitors in Viral C Cirrhosis investigators are listed in the Supplementary.
- ∗
Authors share co-first authorship.